Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: Lower mortality at 1 month but not at 1 year

S. H. Gottlieb, S. C. Achuff, E. D. Mellits, G. Gerstenblith, K. L. Baughman, L. Becker, N. C. Chandra, S. Henley, J. O. Humphries, C. Heck

Research output: Contribution to journalArticle

Abstract

To determine whether prophylactic andiarrhythmic therapy influences mortality in high-risk patients after acute myocardial infarction, 143 such patients were randomized in a double-blind individually dose-adjusted, placebo-controlled trial an average of 14 ± 7 days after myocardial infarction and followed for 1 year. Patients were judged to be at high risk on the basis of (1) ejection fraction less than 40% (n = 60), (2) arrhythmias of Lown class 3 or higher (n = 26), or (3) both (n = 57). Aprindine was chosen because of its half-life, few side effects, and antiarrhythmic efficacy. Baseline characteristics in the treatment arms did not differ. Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p <.001) and at 1 year (p <.001). One patient was lost to follow-up; in the remaining patients 1 year mortality was 20% (28/142; 12 aprindine and 16 placebo). There was no significant difference between the two study arms in overall mortality and sudden death. However, among those who died, median duration of survival was longer in aprindine-treated patients (86 vs 21.5 days) (p = .04). Although antiarrhythmic treatment with aprindine of high-risk patients after myocardial infarction does not affect 1 year survival, mortality appears to be delayed; thus there may be a role for short-treatment before more definitive therapy such as surgery.

Original languageEnglish (US)
Pages (from-to)792-799
Number of pages8
JournalCirculation
Volume75
Issue number4
StatePublished - 1987

Fingerprint

Aprindine
Survivors
Myocardial Infarction
Mortality
Therapeutics
Cardiac Arrhythmias
Placebos
Survival
Lost to Follow-Up
Sudden Death
Half-Life

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction : Lower mortality at 1 month but not at 1 year. / Gottlieb, S. H.; Achuff, S. C.; Mellits, E. D.; Gerstenblith, G.; Baughman, K. L.; Becker, L.; Chandra, N. C.; Henley, S.; Humphries, J. O.; Heck, C.

In: Circulation, Vol. 75, No. 4, 1987, p. 792-799.

Research output: Contribution to journalArticle

@article{3b96b7fab5084653955e2a18370e272b,
title = "Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction: Lower mortality at 1 month but not at 1 year",
abstract = "To determine whether prophylactic andiarrhythmic therapy influences mortality in high-risk patients after acute myocardial infarction, 143 such patients were randomized in a double-blind individually dose-adjusted, placebo-controlled trial an average of 14 ± 7 days after myocardial infarction and followed for 1 year. Patients were judged to be at high risk on the basis of (1) ejection fraction less than 40{\%} (n = 60), (2) arrhythmias of Lown class 3 or higher (n = 26), or (3) both (n = 57). Aprindine was chosen because of its half-life, few side effects, and antiarrhythmic efficacy. Baseline characteristics in the treatment arms did not differ. Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p <.001) and at 1 year (p <.001). One patient was lost to follow-up; in the remaining patients 1 year mortality was 20{\%} (28/142; 12 aprindine and 16 placebo). There was no significant difference between the two study arms in overall mortality and sudden death. However, among those who died, median duration of survival was longer in aprindine-treated patients (86 vs 21.5 days) (p = .04). Although antiarrhythmic treatment with aprindine of high-risk patients after myocardial infarction does not affect 1 year survival, mortality appears to be delayed; thus there may be a role for short-treatment before more definitive therapy such as surgery.",
author = "Gottlieb, {S. H.} and Achuff, {S. C.} and Mellits, {E. D.} and G. Gerstenblith and Baughman, {K. L.} and L. Becker and Chandra, {N. C.} and S. Henley and Humphries, {J. O.} and C. Heck",
year = "1987",
language = "English (US)",
volume = "75",
pages = "792--799",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Prophylactic antiarrhythmic therapy of high-risk survivors of myocardial infarction

T2 - Lower mortality at 1 month but not at 1 year

AU - Gottlieb, S. H.

AU - Achuff, S. C.

AU - Mellits, E. D.

AU - Gerstenblith, G.

AU - Baughman, K. L.

AU - Becker, L.

AU - Chandra, N. C.

AU - Henley, S.

AU - Humphries, J. O.

AU - Heck, C.

PY - 1987

Y1 - 1987

N2 - To determine whether prophylactic andiarrhythmic therapy influences mortality in high-risk patients after acute myocardial infarction, 143 such patients were randomized in a double-blind individually dose-adjusted, placebo-controlled trial an average of 14 ± 7 days after myocardial infarction and followed for 1 year. Patients were judged to be at high risk on the basis of (1) ejection fraction less than 40% (n = 60), (2) arrhythmias of Lown class 3 or higher (n = 26), or (3) both (n = 57). Aprindine was chosen because of its half-life, few side effects, and antiarrhythmic efficacy. Baseline characteristics in the treatment arms did not differ. Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p <.001) and at 1 year (p <.001). One patient was lost to follow-up; in the remaining patients 1 year mortality was 20% (28/142; 12 aprindine and 16 placebo). There was no significant difference between the two study arms in overall mortality and sudden death. However, among those who died, median duration of survival was longer in aprindine-treated patients (86 vs 21.5 days) (p = .04). Although antiarrhythmic treatment with aprindine of high-risk patients after myocardial infarction does not affect 1 year survival, mortality appears to be delayed; thus there may be a role for short-treatment before more definitive therapy such as surgery.

AB - To determine whether prophylactic andiarrhythmic therapy influences mortality in high-risk patients after acute myocardial infarction, 143 such patients were randomized in a double-blind individually dose-adjusted, placebo-controlled trial an average of 14 ± 7 days after myocardial infarction and followed for 1 year. Patients were judged to be at high risk on the basis of (1) ejection fraction less than 40% (n = 60), (2) arrhythmias of Lown class 3 or higher (n = 26), or (3) both (n = 57). Aprindine was chosen because of its half-life, few side effects, and antiarrhythmic efficacy. Baseline characteristics in the treatment arms did not differ. Holter-detected arrhythmias were reduced in aprindine-treated patients at 3 months (p <.001) and at 1 year (p <.001). One patient was lost to follow-up; in the remaining patients 1 year mortality was 20% (28/142; 12 aprindine and 16 placebo). There was no significant difference between the two study arms in overall mortality and sudden death. However, among those who died, median duration of survival was longer in aprindine-treated patients (86 vs 21.5 days) (p = .04). Although antiarrhythmic treatment with aprindine of high-risk patients after myocardial infarction does not affect 1 year survival, mortality appears to be delayed; thus there may be a role for short-treatment before more definitive therapy such as surgery.

UR - http://www.scopus.com/inward/record.url?scp=0023136458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023136458&partnerID=8YFLogxK

M3 - Article

C2 - 3549043

AN - SCOPUS:0023136458

VL - 75

SP - 792

EP - 799

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 4

ER -